(Q33706729)

English

Rituximab

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

Rituximab (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Onrust SV

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Lamb HM

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Balfour JA

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

1 July 1999

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

79-88; discussion 89-90

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

https://scigraph.springernature.com/pub.10.2165/00003495-199958010-00009

0 references

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mantle-cell lymphoma: classification and therapeutic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history of and therapy for the indolent non-Hodgkin's lymphomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical practice guidelines: non-Hodgkin's lymphomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/10439931

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199958010-00009

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33706729&oldid=1529411574"